About Us

BioVentures Investors has forged a reputation of trust, integrity, performance and professionalism that is sought after by the leadership of emerging medtech companies.

We believe that technology is a key enabler in finding new ways to increase efficiency and quality, and to create value in the delivery of healthcare.

Our investment thesis is driven by key worldwide trends, including:

A growing population of 65 years of age and older. By 2060:

  • One quarter of the U.S. population will be 65 or older
  • The population of 65 and older will more than double

Tremendous pressure on all governmental and private healthcare spending. By 2020:

  • U.S. health expenditures will exceed $4.5 trillion
  • Worldwide health expenditures are anticipated to exceed $14 trillion

A steady increase in chronic diseases: By 2020:

  • Nearly half (49%) of the U.S. population will be affected by chronic disease

As a result, there is a global and universal need to deliver more healthcare to more people more efficiently.

This efficiency is more likely to come from the application of technologies developed outside of healthcare and applied in a disruptive fashion, than from new therapeutic drugs. BVI has established a superior track record over fifteen years of investing in such disruptive innovation.


Why We
Invest in

Medtech is the application of technology to healthcare that provides practical and effective solutions to critical healthcare issues

Medtech is the driving force behind the efficient delivery of medical treatments that have lower costs, improved outcomes and increases in quality of life.

The medtech sector is currently in a period of active innovation and expansion. Key factors fueling this trend include:

  • A growing and aging population with an increase in chronic diseases such as stroke, cardiovascular disease, diabetes, hypertension and arthritis, many of which cannot be treated with therapeutic drugs
  • Alignment with a global need for governments to deliver better healthcare to an increasing number of people more efficiently
  • A rise in M&A transactions, especially for products that enable efficient outcomes thereby justifying their value
  • Shorter investment duration and lower risk profile than therapeutic drugs



Deal Flow


Our partners have over 150 years of collective industry experience. This experience allows us to derive most of our investments through direct, personal contacts with:

  • Research laboratories
  • University and hospital technology transfer offices
  • Innovators in the medical community, including scientists, physicians, engineers, advisors and key opinion leaders
  • Members of senior management known to us through previous ventures

For many of the companies in which we invest, we are the first, and sometimes the only, institutional investor shown the opportunity based on our hard-earned reputation in the medtech market whereby emerging companies directly seek access to our guidance and capital to achieve “next-level” performance.